Use and possible abuse of fibrinogen.

M. Karrer,T. Lebherz

Abstract:

What problem does this paper attempt to address?

Opioid Analgesics-Related Pharmacokinetic Drug Interactions: from the Perspectives of Evidence Based on Randomized Controlled Trials and Clinical Risk Management

Xiu-Qin Feng,Ling-Ling Zhu,Quan Zhou

DOI: https://doi.org/10.2147/jpr.s138698

IF: 2.8319

2017-01-01

Journal of Pain Research

Abstract:BACKGROUND:Multimorbidity results in complex polypharmacy which may bear a risk of drug interactions. A better understanding of opioid analgesics combination therapy used for pain management could help warrant medication safety, efficacy, and economic relevance. Until now there has been no review summarizing the opioid analgesics-related pharmacokinetic drug interactions from the perspective of evidence based on randomized controlled trials (RCTs).METHOD:A literature search was performed using PubMed, MEDLINE, and the Cochrane Library, using a PRISMA flowchart.RESULTS:Fifty-two RCTs were included for data interpretation. Forty-two RCTs (80.8%) were conducted in healthy volunteers, whereas 10 RCTs (19.2%) enrolled true patients. None of the opioid-drug/herb pairs was listed as contraindications of opioids involved in this review. Circumstances in which opioid is comedicated as a precipitant drug include morphine-P2Y12 inhibitors, morphine-gabapentin, and methadone-zidovudine. Circumstances in which opioid is comedicated as an object drug include rifampin-opioids (morphine, tramadol, oxycodone, methadone), quinidine-opioids (morphine, fentanyl, oxycodone, codeine, dihydrocodeine, methadone), antimycotics-opioids (buprenorphine, fentanyl, morphine, oxycodone, methadone, tilidine, tramadol), protease inhibitors-opioids (ritonavir, ritonavir/lopinavir-oxycodone, ritonavir-fentanyl, ritonavir-tilidine), grapefruit juice-opioids (oxycodone, fentanyl, methadone), antidepressants-opioids (paroxetine-tramadol, paroxetine-hydrocodone, paroxetine-oxycodone, escitalopram-tramadol), metoclopramide-morphine, amantadine-morphine, sumatriptan-butorphanol nasal sprays, ticlopidine-tramadol, St John's wort-oxycodone, macrolides/ketolides-oxycodone, and levomepromazine-codeine. RCTs investigating the same combination, almost unanimously, drew consistent conclusions, except two RCTs on amantadine-intravenous morphine combination where a different amantadine dose was used and two RCTs on morphine-ticagrelor combination where healthy volunteers and true patients were enrolled, respectively. RCTs investigating in true patients may reflect a realistic clinical scenario and overcome the limitation of RCTs performed in healthy volunteers under standardized conditions. Further research opportunities are also presented in this review.CONCLUSION:Effective and safe combination therapy of opioids can be achieved by promoting the awareness of potential changes in therapeutic efficacy and toxicities, prescribing alternatives or changing administration strategy, tailoring dose, reviewing the appropriateness of orders, and paying attention to medication monitoring.
Updated Clinical Pharmacokinetics and Pharmacodynamics of Oxycodone

Mari Kinnunen,Panu Piirainen,Hannu Kokki,Pauliina Lammi,Merja Kokki

DOI: https://doi.org/10.1007/s40262-018-00731-3

2019-01-17

Clinical Pharmacokinetics

Abstract:Global oxycodone consumption has increased sharply during the last two decades, and, in 2008, oxycodone consumption surpassed that of morphine. As oxycodone was synthesized in 1916 and taken to clinical use a year later, it has not undergone the same approval process required by today’s standards. Most of the basic oxycodone pharmacokinetic (PK) data are from the 1990s and from academic research; however, a lot of additional data have been published over the last 10 years. In this review, we describe the latest oxycodone data on special populations, including neonates, children, pregnant and lactating women, and the elderly. A lot of important drug interaction data have been published that must also be taken into account when oxycodone is used concomitantly with cytochrome P450 (CYP) 3A inducers and inhibitors and/or CYP2D6 inhibitors. In addition, we gathered data on abuse-deterrent oxycodone formulations, and the PK of alternate administration routes, i.e. transmucosal and epidural, are also described.

pharmacology & pharmacy
Development of Oxycodone in Clinical Treatment

Du-xiao ZHANG,Wei-hong GE,Feng YU,han XIE

DOI: https://doi.org/10.13664/j.cnki.pcr.2014.06.013

2014-01-01

Abstract:Oxycodone is a central nervous system opioid analgesics reformed from thebaine. In recent years, with the development of the formulation of oxycodone, it has been an effective treatment for acute pain and chronic pain. In addition, oxycodone plus opioid receptor antagonist has been developed to improve analgesia in clinical. This article reviews the basic pharmacological properties of oxycodone and its clinical treatment development.
EPR studies of the cytochrome b-c 1 segment of the mitochondrial electron transfer system.

N. Orme-Johnson,R. E. Hansen,H. Beinert

DOI: https://doi.org/10.1016/0006-291X(71)90419-0

1971-11-19

Abstract:
Untangling the complexity of opioid receptor function

Rita J. Valentino,Nora D. Volkow

DOI: https://doi.org/10.1038/s41386-018-0225-3

2018-09-24

Neuropsychopharmacology

Abstract:Mu opioid receptor agonists are among the most powerful analgesic medications but also among the most addictive. The current opioid crisis has energized a quest to develop opioid analgesics that are devoid of untoward effects. Since their discovery in the 1970’s, there have been major advances in our understanding of the endogenous opioid systems that these drugs target. Yet many questions remain and the development of non-addictive opioid analgesics has not been achieved. However, access to new molecular, genetic and computational tools have begun to elucidate the structural dynamics of opioid receptors, the scaffolding that links them to intracellular signaling cascades, their cellular trafficking and the distinct ways that various opioid drugs modify them. This mini-review highlights some of the chemical and pharmacological findings and new perspectives that have arisen from studies using these tools. They reveal multiple layers of complexity of opioid receptor function, including a spatiotemporal specificity in opioid receptor-induced cellular signaling, ligand-directed biased signaling, allosteric modulation of ligand interactions, heterodimerization of different opioid receptors, and the existence of slice variants with different ligand specificity. By untangling these layers, basic research into the chemistry and pharmacology of opioid receptors is guiding the way towards deciphering the mysteries of tolerance and physical dependence that have plagued the field and is providing a platform for the development of more effective and safer opioids.

pharmacology & pharmacy,neurosciences,psychiatry
Revisiting dezocine for opioid use disorder: A narrative review of its potential abuse liability

Gordon A. Barr,Heath D. Schmidt,Ashish P. Thakrar,Henry R. Kranzler,Renyu Liu

DOI: https://doi.org/10.1111/cns.70034

2024-09-20

CNS Neuroscience & Therapeutics

Abstract:Dezocine is a partial MOR agonist previously used clinically in the USA and currently in China. It has been proposed that dezocine be reintroduced to clinical use in the USA, as an analgesia and/or an additional tool to treat opioid use disorder. To consider the clinical reintroduction of dezocine knowing its abuse liability is important. In this review, we found no reports of abuse, dependence or overdose in the English literature, and a small number of cases of dependence in the Chinese literature. If it is less or non‐addictive than other opioids, its short half‐life would allow it to bridge to other medication assisted therapies, facilitate tapering of opioid use and perhaps be used as a rescue medication in those trying to reduce opioid use. Aims Opioid use disorder (OUD) remains a serious public health problem. Opioid maintenance treatment is effective but under‐utilized, hard to access under existing federal regulations, and, once patients achieve OUD stability, challenging to discontinue. Fewer than 2% of persons with OUD stop using opioids completely. There have been calls from public advocacy groups, governmental agencies, and public health officials for new treatments for OUD. Dezocine, a non‐scheduled opioid previously used in the United States and currently widely prescribed in China for pain management, could be a candidate for a novel OUD treatment medication in the U.S. Nonetheless, to date, there have been no reviews of the clinical and preclinical literature detailing dezocine's abuse potential, a key consideration in assessing its clinical utility. Discussion There are no English language reports of human abuse, dependence, or overdose of dezocine, despite years of extensive clinical use. There are a few case reports of dezocine abuse in the Chinese literature, but there are no reports of overdose deaths. Dezocine is perceived as an opioid and is "liked" by opioid‐experienced human and non‐human primates, properties that are not dose‐dependent and are mitigated by ceiling effects—higher doses do not result in more "liking." There is little withdrawal, spontaneous or precipitated, in humans, monkeys, rats, or mice treated chronically with dezocine alone. However, at some doses, dezocine can precipitate withdrawal in humans and monkeys dependent on other opioids. In rodents, dezocine reduces the severity of morphine withdrawal and the rewarding properties of other opioids. Conclusions Although dezocine is reinforcing in humans and monkeys with prior or concurrent opioid use within a restricted dose range, there are only a few anecdotal reports of dezocine abuse despite of the long history of use in humans. Given the evidence of dezocine's limited abuse potential, it could be useful both as a treatment for OUD. However, in‐depth studies would be required for dezocine to be re‐considered for clinical use.

pharmacology & pharmacy,neurosciences
Abuse Potential of Intravenous Oxycodone/Naloxone Solution in Nondependent Recreational Drug Users

Salvatore V. Colucci,Peter J. Perrino,Megan Shram,Cynthia Bartlett,Yi Wang,Stephen C. Harris

DOI: https://doi.org/10.1007/s40261-014-0192-3

2014-04-23

Clinical Drug Investigation

Abstract:Background and ObjectiveAbuse of opioid analgesics has become a public health issue. Some opioid abusers use intravenous administration to increase the magnitude of positive reinforcing effects. Intravenous co-administration of oxycodone with naloxone, an opioid antagonist, may reduce these rewarding effects and discourage abuse. A 2:1 oxycodone:naloxone (OXN) tablet formulation has been studied in the USA for the management of moderate-to-severe chronic pain. Intravenous administration of a 2:1 oxycodone:naloxone solution (sOXN) reflects the oxycodone:naloxone ratio found in laboratory studies of OXN following tampering for intravenous administration. The objective of this study was to characterize abuse-deterrent properties of sOXN.MethodsThis single-center, double-blind, randomized, placebo-controlled, active-controlled, crossover study enrolled nondependent recreational opioid users with experience using multiple (two or more) routes of administration. Following demonstration that subjects could discern between placebo and oxycodone, 24 eligible male and female subjects were randomized to receive intravenous injections of 0.07 mg/kg oxycodone (OXY), 0.07 mg/kg oxycodone and 0.035 mg/kg naloxone solution (sOXN), or matching placebo over three visits. Pharmacokinetics, pharmacodynamics, safety, and tolerability were assessed at scheduled times up to 8 h post-dose. Parameters were computed and statistically compared among treatments.ResultsPharmacokinetics were similar between OXY and sOXN. Subjects reported significantly fewer rewarding effects with sOXN compared with OXY; differences between sOXN and placebo were generally not significant. sOXN was well tolerated.ConclusionsSignificant reductions in drug liking and other subjective effects following administration of sOXN compared with OXY indicate that naloxone concentrations were sufficient to antagonize the effects of oxycodone when abused by the intravenous route of administration in opioid-experienced drug users.

pharmacology & pharmacy
Opioid analgesia: recent developments

Christoph Stein

DOI: https://doi.org/10.1097/SPC.0000000000000495

Abstract:Purpose of review: Opioids are potent drugs for the treatment of severe pain, but they are burdened by detrimental side-effects, such as respiratory depression, addiction, sedation and constipation. Their clinical application is undisputed in acute (e.g. perioperative) and cancer pain, but their use in chronic nonmalignant pain has met increasing scrutiny and has contributed to the opioid crisis. Thus, novel analgesics with reduced side-effects are badly needed. Recent findings: Current research topics include enkephalinase inhibitors, allosteric and multivalent ligands, biased opioid receptor signaling and selective activation of peripheral opioid receptors in injured tissues. Summary: Opioids still appear to be most promising among current approaches in the development of analgesics. Basic knowledge about pathophysiology of clinical pain and novel insights in pharmacology suggest that the most interesting perspectives are augmenting endogenous opioid actions and selectively targeting peripheral opioid receptors. The latter approach is additionally supported by evidence from clinical studies. Some biased, multivalent and peripherally selective agonists have advanced to phase III trials, but novel drugs have not become available for clinical application. Future strategies in analgesic drug development might include public-private partnerships and nonprofit pharmaceutical companies, as exemplified by the AIDS crisis and proposals to combat antibiotic resistance.
IUPHAR review: Recent progress in the development of Mu opioid receptor modulators to treat opioid use disorders

Piyusha P. Pagare,Rachael Flammia,Yan Zhang

DOI: https://doi.org/10.1016/j.phrs.2023.107023

IF: 10.334

2024-01-01

Pharmacological Research

Abstract:Opioid Use Disorder (OUD) can be described as intense preoccupation with using or obtaining opioids despite the negative consequences associated with their use. As the number of OUD cases in the U.S. increase, so do the number of opioid-related overdose deaths. In 2022, opioid-related overdose became the No. 1 cause of death for individuals in the U.S. between the ages of 25 and 64 years of age. Because of the introduction of highly potent synthetic opioids (e.g. fentanyl) to the illicit drug market, there is an urgent need for therapeutics that successfully reduce the number of overdoses and can help OUD patients maintain sobriety. Most abused opioids stimulate the mu-opioid receptor (MOR) and activation of this receptor can lead to positive (e.g., euphoria) consequences. However, the negative side effects of MOR stimulation can be fatal (e.g., sedation, respiratory depression). Therefore, the MOR is an attractive target for developing medications to treat OUD. Current FDA drugs include MOR agonists that aid in detoxification and relapse prevention, and MOR antagonists that also serve as maintenance therapies or reverse overdose. These medications are limited by their abuse potential, adverse effects, or pharmacological profiles which leaves ample room for research into designing new chemical entities with optimal physiological effects. These includes, orthosteric ligands that target the primary binding site of the MOR, allosteric ligands that positively, negatively, or "silently" modulate receptor function, and lastly, bitopic ligands target both the orthosteric and allosteric sites simultaneously.
Morphinan Evolution: The Impact of Advances in Biochemistry and Molecular Biology

Keita Kajino,Akihisa Tokuda,Tsuyoshi Saitoh

DOI: https://doi.org/10.1093/jb/mvae021

2024-02-21

The Journal of Biochemistry

Abstract:Abstract Morphinan-based opioids, derived from natural alkaloids like morphine, codeine and thebaine, have long been pivotal in managing severe pain. However, their clinical utility is marred by significant side effects and high addiction potential. This review traces the evolution of the morphinan scaffold in light of advancements in biochemistry and molecular biology, which have expanded our understanding of opioid receptor pharmacology. We explore the development of semi-synthetic and synthetic morphinans, their receptor selectivity and the emergence of biased agonism as a strategy to dissociate analgesic properties from undesirable effects. By examining the molecular intricacies of opioid receptors and their signaling pathways, we highlight how receptor-type selectivity and signaling bias have informed the design of novel analgesics. This synthesis of historical and contemporary perspectives provides an overview of the morphinan landscape, underscoring the ongoing efforts to mitigate the problems facing opioids through smarter drug design. We also highlight that most morphinan derivatives show a preference for the G protein pathway, although detailed experimental comparisons are still necessary. This fact underscores the utility of the morphinan skeleton in future opioid drug discovery.

biochemistry & molecular biology
Blocking Potential Metabolic Sites on NAT to Improve Its Safety Profile While Retaining the Pharmacological Profile

Rachael Flammia,Boshi Huang,Piyusha P. Pagare,Celsey M. St Onge,Abeje Abebayehu,James C. Gillespie,Rolando E. Mendez,Dana E. Selley,William L. Dewey,Yan Zhang

DOI: https://doi.org/10.1016/j.bioorg.2024.107489

IF: 5.307

2024-01-01

Bioorganic Chemistry

Abstract:The number of opioid-related overdose deaths and individuals that have suffered from opioid use disorders have significantly increased over the last 30 years. FDA approved maintenance therapies to treat opioid use disorder may successfully curb drug craving and prevent relapse but harbor adverse effects that reduce patient compliance. This has created a need for new chemical entities with improved patient experience. Previously our group reported a novel lead compound, NAT, a mu-opioid receptor antagonist that potently antagonized the antinociception of morphine and showed significant blood-brain barrier permeability. However, NAT belongs to thiophene containing compounds which are known structural alerts for potential oxidative metabolism. To overcome this, 15 NAT derivatives with various substituents at the 5'-position of the thiophene ring were designed and their structure-activity relationships were studied. These derivatives were characterized for their binding affinity, selectivity, and functional activity at the mu opioid receptor and assessed for their ability to antagonize the antinociceptive effects of morphine in vivo. Compound 12 showed retention of the basic pharmacological attributes of NAT while improving the withdrawal effects that were experienced in opioid-dependent mice. Further studies will be conducted to fully characterize compound 12 to examine whether it would serve as a new lead for opioid use disorder treatment and management.
Pharmacology of opioids in the treatment of chronic pain syndromes

Ricardo Vallejo,Robert L Barkin,Victor C Wang

IF: 4.396

Pain Physician

Abstract:The perpetual pursuit of pain elimination has been constant throughout human history and pervades human cultures. In some ways it is as old as medicine itself. Cultures throughout history have practiced the art of pain management through remedies such as oral ingestion of herbs or techniques believed to have special properties. In fact, even Hippocrates wrote about the practice of trepanation, the cutting of holes in the body to release pain. Current therapies for management of pain include the pervasive utilization of opioids, which have an extensive history, spanning centuries. There is general agreement about the appropriateness of opioids for the treatment of acute and cancer pain, but the long-term use of these drugs for treatment of chronic non-malignant pain remains controversial. The pros and cons regarding these issues are beyond the scope of this review. Instead, the purpose of this review will be directed towards the pharmacology of commonly prescribed opioids in the treatment of various chronic pain syndromes. Opium, derived from the Greek word for "juice," is extracted from the latex sap of the opium poppy (Papaverum somniferum). The juice of the poppy is the source of some 20 different alkaloids of opium. These alkaloids of opioids can be divided into 2 chemical classes: phenanthrenes (morphine, codeine, and thebaine) and benzylisoquinolines (agents that do not interact with opioid receptors).
Global Trends in Oliceridine (TRV130) Research from 2013 to 2024: A Bibliometrics and Knowledge Graph Analysis

Cong Wang,Lidan Liu,Xue Bai

DOI: https://doi.org/10.2147/dddt.s475205

IF: 4.3188

2024-10-22

Drug Design Development and Therapy

Abstract:Cong Wang, 1 Lidan Liu, 1 Xue Bai 2 1 Department of Anesthesiology, Shengjing Hospital of China Medical University, Shenyang, Liaoning Province, People's Republic of China; 2 Department of Health Management, Shengjing Hospital of China Medical University, Shenyang, Liaoning Province, People's Republic of China Correspondence: Xue Bai, Department of Health Management, Shengjing Hospital of China Medical University, No. 36 Sanhao Street, Heping District, Shenyang, Liaoning Province, 110004, People's Republic of China, Email Purpose: The adverse effects and drug abuse issues associated with opioid drugs have made finding a safe and effective alternative a focus of research. Oliceridine has attracted attention for its lower adverse reactions, such as respiratory depression and gastrointestinal issues, compared to traditional opioids, and is considered a promising candidate for addressing the current limitations in opioid therapy. This article explored the knowledge structure of oliceridine through bibliometric analysis, highlighting its clinical applications in managing acute pain and its mechanisms that may reduce addiction risk. Our bibliometric analysis highlighted hotspots and trends in oliceridine research, guiding future studies on its safety and efficacy in pain management. Methods: This study utilized the Web of Science Core Collection database to search for articles related to oliceridine from 2013 to 2024. Systematic analysis was conducted on publication, country, institution, author, journal, references, and keywords. The software Citespace, Vosviewer, and Bibliometrix were employed to visualize bibliometric analysis. Results: From 2013 to 2024, 159 articles on oliceridine were published in 98 journals by 158 institutions from 28 countries. The United States has rapidly developed in this field, providing significant momentum. Keyword clustering analysis revealed that research on oliceridine primarily focused on exploring its molecular and pharmacological mechanisms and conducting clinical studies to evaluate its efficacy and safety in pain management. Analyses of the strongest citation bursts with references and keywords indicated that protein-biased ligands and oliceridine were hotspots. The emergence of divergent views regarding oliceridine's biased agonism will lead to future hotspots focusing on the underlying mechanisms of biased signaling by G protein-coupled receptors and drug design. Conclusion: Bibliometric analysis provides insights into the current hotspots and emerging areas of oliceridine, which can guide future research. The widespread attention and clinical application of oliceridine lay a solid foundation for further drug development and clinical trials. Keywords: opioid receptors, biased agonism, oliceridine, bibliometrics Pain represents a global public health issue, with opioid medications considered the primary choice for effective pain relief. However, adverse reactions associated with opioid drugs can limit their optimal analgesic dosage. These adverse reactions decrease patient compliance and reduce their quality of life. Moreover, the abuse of opioid drugs is a significant social problem. Therefore, the objective of opioid analgesic drug development has consistently been to create μ-opioid receptor agonists with high affinity and specificity. The μ-opioid receptor belongs to the G protein-coupled receptor family, which is a cell surface receptor that binds to extracellular substances and transmits intracellular signals through G proteins. 1 The interaction of opioid drugs with the μ-opioid receptor triggers signaling through the G protein and the β-arrestin pathways. Stimulation of the G protein pathway produces analgesic effects. In contrast, activation of the β-arrestin pathway is associated with opioid-related adverse events. 2 The focus on biased agonism is crucial because it allows for the selective activation of the G protein pathway while minimizing β-arrestin activation. This differentiation has the potential to separate therapeutic benefits from harmful side effects, leading to safer pain management options and a reduced risk of opioid-related complications. In attempts to reduce side effects, an increasingly exciting area is the design of opioid drugs that activate one pathway rather than another. 3–8 Bohn and colleagues found that morphine maintained its analgesic efficacy without tolerance in β-arrestin 2 gene knockout animals, which subsequently led to the development of TRV130. 9,10 TRV130 is a novel G protein-biased μ-opioid receptor agonist. It activates G protein signaling while causing minimal recruitment of β-arrestin proteins. 3 Trevena led the development of TRV130, later -Abstract Truncated-

pharmacology & pharmacy,chemistry, medicinal
Characterization of Oxycodone Misuse using National Survey Data.

Christopher Holstege,Kawai Tanabe,Moira Smith,Saumitra Rege,Will Goodrich

DOI: https://doi.org/10.5811/westjem.58904

2024-01-24

Western Journal of Emergency Medicine

Abstract:Objectives: The objective of the study is to characterize the risk markers of oxycodone misuse using the nationally representative National Survey of Drug Use and Health (NSDUH) data.Background: Drug overdoses continues to be a public health crisis with 70,630 fatalities in 2019. Approximately two-thirds of these deaths (66%) involved a prescription or illicit opioid. Synthetic opioids accounted for 72.9% of opioid-involved overdose deaths in 2019.Methods: The 2019 NSDUH public use cross-sectional data were analyzed. The respondents were classified into two groups, past year oxycodone misusers and non-misusers, based on the screening questions assessing past year misuse of oxycodone products. The prevalence of selected demographic, clinical factors and substance use and abuse, including prescription medications, was assessed descriptively for the two population groups using cross tabulated frequencies and chi-square tests. Logistic regression models using a backward selection process were used to identify predictors of oxycodone misuse adjusting for covariates. Adjusted odds ratios (OR) and corresponding 95% Confidence Intervals (CI) were calculated.Results: Overall, the 2019 NSDUH survey comprised of 56,136 respondents, of which 4,359 respondents (7.7%) reported using oxycodone products over the last year. Furthermore, 770 respondents reported misuse, accounting for 17.6% of the total oxycodone users or 1.4% of the survey sample. The proportion of past year oxycodone misusers was higher in males (54.1% vs 44.6%, p<0.001), unmarried (69.6% vs 44.8%, p<0.001), and Hispanic (16.3% vs 13.4%, p<0.001). Suicide ideation was much more frequent in oxycodone misusers (19.8% vs 10.1%, p<0.001). The prevalence of use and misuse of other substances in the previous year was significantly higher in the oxycodone misusers. Previous year marijuana use (OR: 1.90, 95% CI: 1.41 – 2.57) was a significant predictor of oxycodone misuse while morphine users were 40% less likely to misuse oxycodone (OR: 0.60, 95% CI: 0.37 – 0.98). Similarly, hydrocodone use reduced the risk of oxycodone misuse by 64% (OR: 0.36, 95% CI: 0.26 – 0.50).Self-reports of obtaining the oxycodone from sources other than the doctors increased the risk of oxycodone misuse by 96% (OR: 1.96, 95% CI: 1.38 – 2.81). Hispanics (OR: 1.34, 95% CI: 1.02 – 1.55) had a significantly higher probability to misuse oxycodone. Oxycodone misuse was significantly more likely among misusers of other opioids including morphine (OR: 5.19, 95% CI: 1.62 – 15.12) and buprenorphine (OR: 2.42, 95% CI: 1.12 – 5.25). Previous year benzodiazepines misusers (OR: 2.44, 95% CI: 1.62 – 3.67), stimulant misusers (OR: 2.68, 95% CI: 1.71 – 4.21) increased the risk for oxycodone misuse in the past year. Males (OR: 1.60, 95% CI: 1.19 – 2.14) and individuals receiving medications for mental health treatment reported a higher risk of oxycodone misuse (OR: 1.46, 95% CI: 1.02 – 2.09).Conclusion: The current study used data from a nationally representative sample and indicated a high prevalence of oxycodone misuse. Our study highlighted risk factors associated with misuse of oxycodone, including gender, use and misuse of other substances including other opioids appear to be important predictors of oxycodone misuse. Tailored interventions and risk-screening measures to optimize oxycodone prescribing might be key in limiting the misuse and diversion of tis pain medication.

emergency medicine
Preclinical Characterization and Development on NAQ As a Mu Opioid Receptor Partial Agonist for Opioid Use Disorder Treatment

Piyusha P. Pagare,Samuel Obeng,Boshi Huang,Madison M. Marcus,Katherine L. Nicholson,Andrew E. Townsend,Matthew L. Banks,Yan Zhang

DOI: https://doi.org/10.1021/acsptsci.2c00178

IF: 6

2022-01-01

ACS Pharmacology & Translational Science

Abstract:Mu opioid receptor (MOR) selective antagonists and partial agonists have clinical utility for the treatment of opioid use disorders (OUDs). However, the development of many has suffered due to their poor pharmacokinetic properties and/or rapid metabolism. Our recent efforts to identify MOR modulators have provided 17-cyclopropylmethyl-3,14 beta-dihydroxy-4,5 alpha-epoxy-6 alpha- (isoquinoline-3-carboxamido)morphinan (NAQ), a low-efficacy partial agonist, that showed sub-nanomolar binding affinity to the MOR (Ki 0.6 nM) with selectivity over the delta opioid receptor (6/mu 241) and the kappa opioid receptor (K/mu 48). Its potent inhibition of the analgesic effect of morphine (AD50 0.46 mg/kg) and precipitation of significantly less withdrawal symptoms even at 100-fold greater dose than naloxone represents a promising molecule for further development as a novel OUD therapeutic agent. Therefore, further in vitro and in vivo characterization of its pharmacokinetics and pharmacodynamics properties was conducted to fully understand its pharmaceutical profile. NAQ showed favorable in vitro ADMET properties and no off-target binding to several classes of GPCRs, enzymes, and ion channels. Following intravenous administration, 1 mg/kg dose of NAQ showed a similar in vivo pharmacokinetic profile to naloxone; however, orally administered 10 mg/kg NAQ demonstrated significantly improved oral bioavailability over both naloxone and naltrexone. Abuse liability assessment of NAQ in rats demonstrated that NAQ functioned as a less potent reinforcer than heroin. Chronic 5 day NAQ pretreatment decreased heroin self-administration in a heroin-vs-food choice procedure similar to the clinically used MOR partial agonist buprenorphine. Taken together, these studies provide evidence supporting NAQ as a promising lead to develop novel OUD therapeutics.
Design, Synthesis, and Biological Evaluation of the Third Generation 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan (NAP) Derivatives As Μ/κ Opioid Receptor Dual Selective Ligands.

Yi Zheng,Samuel Obeng,Huiqun Wang,Abdulmajeed M. Jali,Bharath Peddibhotla,Dwight A. Williams,Chuanchun Zou,David L. Stevens,William L. Dewey,Hamid I. Akbarali,Dana E. Selley,Yan Zhang

DOI: https://doi.org/10.1021/acs.jmedchem.8b01158

IF: 8.039

2019-01-01

Journal of Medicinal Chemistry

Abstract:μ opioid receptor (MOR) agonists have been widely applied for treating moderate to severe pain. However, numerous adverse effects have been associated with their application, including opioid-induced constipation (OIC), respiratory depression, and addiction. On the basis of previous work in our laboratory, NAP, a 6β- N-4'-pyridyl substituted naltrexamine derivative, was identified as a peripheral MOR antagonist that may be used to treat OIC. To further explore its structure-activity relationship, a new series of NAP derivatives were designed, synthesized, and biologically evaluated. Among these derivatives, NFP and NYP significantly antagonized the antinociception effect of morphine. Whereas NAP acted mainly peripherally, its derivatives NFP and NYP actually can act centrally. Furthermore, NFP produced significantly lesser withdrawal symptoms than naloxone at similar doses. These results suggest that NFP has the potential to be a lead compound to treat opioid abuse and addiction.
Review of Opioid Abuse-Deterrent Formulations: Impact and Barriers to Access

DOI: https://doi.org/10.2147/jpr.s457982

IF: 2.8319

2024-06-06

Journal of Pain Research

Abstract:Lynn Webster, 1 Jeffrey Gudin 2 1 Dr. Vince Clinical Research, Overland Park, KS, USA; 2 Department of Anesthesiology and Pain Management, University of Miami, Miller School of Medicine, Miami, FL, USA Correspondence: Lynn Webster, Dr. Vince Clinical Research, 1285 3rd Avenue, Salt Lake City, UT, 84103, USA, Tel +1 801-560-1707, Email The misuse and abuse of opioid analgesics continue to pose a serious public health concern, but for some patients, opioids remain an important analgesic option. Extended-release (ER) opioid formulations are effective for treating chronic pain and are supported by multiple 12-week efficacy studies. ER opioids often contain a high opioid content, and similar to immediate-release (IR) formulations, are subject to abuse, misuse, and diversion. Unintentional misuse may also occur when ER formulations are manipulated for medicinal administration, such as crushing a dose for easier oral intake. As part of a multipronged strategy designed to fight the opioid epidemic, abuse-deterrent formulations (ADFs) were developed to deter misuse, abuse, and diversion of opioids by making manipulation more difficult and nonoral routes of administration less rewarding. Although ADF opioids have been shown to decrease rates of abuse and diversion, they are not equally effective in terms of deterring manipulation for abuse or misuse. Xtampza ER utilizes DETERx technology, which allows it to retain ER characteristics when chewed or crushed, making it the only ER opioid without a boxed warning against these types of manipulation. OxyContin was also developed as an ADF but uses RESISTEC technology, making the tablet hard to crush and viscous in aqueous solutions. ADF utilization has been hampered by patient access issues, including high prices due to lack of insurance coverage. Postmarket real-world studies demonstrate lower rates of abuse, misuse, and diversion for ADF ER opioids compared with non-ADF formulations. However, similar studies comparing abuse-related effectiveness and health care costs for ADF opioids are warranted if clinicians are expected to utilize these potentially safer opioid formulations. These studies would support further education surrounding the benefits and utilization of ADFs and manipulation potential of different ADFs. Keywords: opioid analgesics, opioid crisis, chronic pain, tamper, abuse-deterrent, extended release Pain and chronic pain (lasting >3 months) are unpleasant sensory and emotional experiences associated with or resembling those associated with potential or actual tissue damage, which are highly debilitating and affect the quality of life of many adults in the US. 1–3 In 2021, an estimated 51.6 million adults in the US were affected by chronic pain and 17.1 million adults experienced high-impact chronic pain, defined as having pain every day or on most days during a 3-month period that substantially restricted participation in life or work activities. 2 Despite opioid misuse and abuse posing a serious and challenging public health problem, for a subset of patients with refractory pain, opioid analgesics remain an important component of pain management. 4 Common prescription opioids (limited to natural, semisynthetic, and methadone) were involved in 17,000 deaths (45 deaths per day) in the US in 2021. 5 Opioid use disorder (OUD) diagnoses and fatal overdoses increased dramatically during the COVID-19 pandemic. 6 A recent analysis by the Joint Economic Committee estimated that in 2020, the economic burden of illicit and licit opioid abuse and misuse reached almost $1.5 trillion. 7 A separate analysis considering the societal costs of OUD and opioid overdose deaths found that the greatest loss was the reduced quality of life from OUD and the value of life lost due to fatal opioid overdose. 8 These findings illustrate the magnitude of OUD as a persistent public health crisis and the devastating impact it has on individuals, families, and society. Support for opioid treatment has come under scrutiny despite therapeutic benefit. Regulatory agencies including the US Food and Drug Administration (FDA) encourage the development of abuse-deterrent formulations (ADF) as part of a multipronged approach for combating opioid misuse and abuse while ensuring that appropriate patients are treated effectively. The aim of this review is to discuss the properties of the available ADF products with evidence for abuse deterrence (eg, physical and chemical barriers) and how these properties may reduce abuse potential. The barriers that limit access to effective opioid treatment are also discussed. A trial of opioid therapy may be warranted if conservative and interventional analgesic treatments fail, and an individual's risk for OUD should be taken into considerat -Abstract Truncated-

clinical neurology
Synthetic opioids: a review and clinical update

Abu Shafi,Alex J. Berry,Harry Sumnall,David M. Wood,Derek K. Tracy

DOI: https://doi.org/10.1177/20451253221139616

2022-01-01

Therapeutic Advances in Psychopharmacology

Abstract:The term ‘opioids’ refers to both the natural compounds (‘opiates’) which are extracted from the opium poppy plant ( Papaver somniferum) and their semi-synthetic and synthetic derivatives. They all possess relatively similar biochemical profiles and interact with the opioid receptors within the human body to produce a wide range of physiological effects. They have historically been used for medicinal purposes, their analgesic and sedative effects, and in the management of chronic and severe pain. They have also been used for non-medicinal and recreational purposes to produce feelings of relaxation, euphoria and well-being. Over the last decade, the emergence of an illegal market in new synthetic opioids has become a major global public health issue, associated with a substantial increase in unintentional overdoses and drug-related deaths. Synthetic opioids include fentanyl, its analogues and emerging non-fentanyl opioids. Their popularity relates to changes in criminal markets, pricing, potency, availability compared to classic opioids, ease of transport and use, rapid effect and lack of detection by conventional testing technologies. This article expands on our previous review on new psychoactive substances. We now provide a more in-depth review on synthetic opioids and explore the current challenges faced by people who use drugs, healthcare professionals, and global public health systems.

pharmacology & pharmacy,psychiatry
Effects of smoking on odour identification in Japanese subjects.

T. Ishimaru,Megumi Fujii

2007-09-01

Abstract:OBJECTIVES Effects of smoking on olfaction appear to be well-known. However, there are not many studies that studied these effects on the basis of olfactory testing, and no studies on this topic have been performed so far in an Asian population. Thus, the aim of this study was to investigate the effects of smoking on odour identification. METHODS Five hundred fifty seven Japanese subjects (368 men and 189 women) were given the cross-cultural smell identification test (CC-SIT). Their history was taken with special regard to nasal disease and smoking. Urine nicotine level was assessed in 107 subjects. RESULTS The CC-SIT scores of current and previous smokers were lower than those of nonsmoking subjects (p < 0.05). The Brinkman index (BI) and CC-SIT score were correlated even when controlling for the subjects' age (r = -0.24, p < 0.001). The time since quitting cigarette smoking did not exhibit a relation with the CC-SIT score (r = -0.04, p = 0.76). In addition, urine levels of nicotine and its metabolites exhibited no significant correlation with the CC-SIT score (r = -0.08, p = 0.40). CONCLUSION Smoking reduces olfactory function. Apparently, recovery of olfactory sensitivity after cessation of smoking appears to be exceptional.
Treatment of overdose in the synthetic opioid era

Phil Skolnick

DOI: https://doi.org/10.1016/j.pharmthera.2021.108019

Abstract:Overdose deaths are often viewed as the leading edge of the opioid epidemic which has gripped the United States over the past two decades (Skolnick, 2018a). This emphasis is perhaps unsurprising because opioid overdose is both the number-one cause of death for individuals between 25 and 64 years old (Dezfulian et al., 2021) and a significant contributor to the decline in average lifespan (Dowell et al., 2017). Exacerbated by the COVID 19 pandemic, it was estimated there were 93,400 drug overdose deaths in the United States during the 12 months ending December 2020, with more than 69,000 (that is, >74%) of these fatalities attributed to opioid overdose (Ahmad et al., 2021). However, the focus on mortality statistics (Ahmad et al., 2021; Shover et al., 2020) tends to obscure the broader medical impact of nonfatal opioid overdose. Analyses of multiple databases indicate that for each opioid-induced fatality, there are between 6.4 and 8.4 non-fatal overdoses, exacting a significant burden on both the individual and society. Over the past 7-8 years, there has been an alarming increase in the misuse of synthetic opioids ("synthetics"), primarily fentanyl and related piperidine-based analogs. Within the past 2-3 years, a structurally unrelated class of high potency synthetics, benzimidazoles exemplified by etonitazene and isotonitazene ("iso"), have also appeared in illicit drug markets (Thompson, 2020; Ujvary et al. 2021). In 2020, it was estimated that over 80% of fatal opioid overdoses in the United States now involve synthetics (Ahmad et al., 2021). The unique physicochemical and pharmacological properties of synthetics described in this review are responsible for both the morbidity and mortality associated with their misuse as well as their widespread availability. This dramatic increase in the misuse of synthetics is often referred to as the "3rd wave" (Pardo et al., 2019; Volkow and Blanco, 2020) of the opioid epidemic. Among the consequences resulting from misuse of these potent opioids is the need for higher doses of the competitive antagonist, naloxone, to reverse an overdose. The development of more effective reversal agents such as those described in this review is an essential component of a tripartite strategy (Volkow and Collins, 2017) to reduce the biopsychosocial impact of opioid misuse in the "synthetic era".

Use and possible abuse of fibrinogen.

Opioid Analgesics-Related Pharmacokinetic Drug Interactions: from the Perspectives of Evidence Based on Randomized Controlled Trials and Clinical Risk Management

Updated Clinical Pharmacokinetics and Pharmacodynamics of Oxycodone

Development of Oxycodone in Clinical Treatment

EPR studies of the cytochrome b-c 1 segment of the mitochondrial electron transfer system.

Untangling the complexity of opioid receptor function

Revisiting dezocine for opioid use disorder: A narrative review of its potential abuse liability

Abuse Potential of Intravenous Oxycodone/Naloxone Solution in Nondependent Recreational Drug Users

Opioid analgesia: recent developments

IUPHAR review: Recent progress in the development of Mu opioid receptor modulators to treat opioid use disorders

Morphinan Evolution: The Impact of Advances in Biochemistry and Molecular Biology

Blocking Potential Metabolic Sites on NAT to Improve Its Safety Profile While Retaining the Pharmacological Profile

Pharmacology of opioids in the treatment of chronic pain syndromes

Global Trends in Oliceridine (TRV130) Research from 2013 to 2024: A Bibliometrics and Knowledge Graph Analysis

Characterization of Oxycodone Misuse using National Survey Data.

Preclinical Characterization and Development on NAQ As a Mu Opioid Receptor Partial Agonist for Opioid Use Disorder Treatment

Design, Synthesis, and Biological Evaluation of the Third Generation 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan (NAP) Derivatives As Μ/κ Opioid Receptor Dual Selective Ligands.

Review of Opioid Abuse-Deterrent Formulations: Impact and Barriers to Access

Synthetic opioids: a review and clinical update

Effects of smoking on odour identification in Japanese subjects.

Treatment of overdose in the synthetic opioid era